InTandem Capital Partners, a middle-market private equity firm focused exclusively on healthcare services, announced the final closing of InTandem Capital Partners Fund III, LP, with $715 million in total capital commitments. And Fund III closed above its original target of $650 million.
Along with predecessor funds, Fund III will continue the Firm’s well-established strategy of making control investments in North American payor, provider, and pharmaceutical services businesses using an operationally intensive, hands-on value creation model. And InTandem partners closely with founders, entrepreneurs and management teams to accelerate transformational growth.
Fund III has secured commitments from a globally diversified group of existing and new investors, including leading endowments, foundations, family offices, healthcare and pension systems, and financial institutions. This fund is already actively investing, having recently completed its third platform deal in Adams Clinical (a multi-site clinical research management organization focused on late-stage outpatient central nervous system trials).
Kirkland and Ellis served as legal counsel for Fund III and Raymond James acted as placement agent.
KEY QUOTES:
“We are delighted and grateful for the success of the fundraising for Fund III. We view the strong support as a testament to the depth and experience of our team and firmwide reputation built over two decades of partnering with healthcare services entrepreneurs. My colleagues and I are committed to working with great determination to deliver compelling returns and reward the trust of our limited partners.”
- Elliot Cooperstone, Managing Partner of InTandem
“Our long-standing focus on the Healthcare Quintuple Aim – the simultaneous pursuit of enhanced patient experience, elevated provider experience, improved clinical outcomes, greater healthcare equity, and lower cost of care delivery – continues to resonate with institutional investors. We believe that investment success is intrinsically linked to alignment with and promotion of the Healthcare Quintuple Aim.”
- Brad Coppens, Senior Partner of InTandem
“We thank our longtime investors for their continued partnership and welcome our new investors joining us in Fund III. We appreciate the confidence our limited partners have placed in us. It is a powerful endorsement of InTandem’s investment strategy.”
- Lauren Mangino, Principal and Head of Investor Relations and Capital Formation at InTandem
